Tissue analysis by artificial intelligence

Nucleai, a promising artificial intelligence (AI) start-up company in the pathology arena is making cancer diagnostics more accurate, accessible and efficient through AI-based analysis of biopsies.

Pathology is ripe for disruption, with a major shortage of pathologists coupled with an increasing demand for biopsies. Research shows that by 2030 the number of active pathologists may drop by 30% compared to 2010 levels.

Nucleai is addressing this by utilising decades of cumulative experience in AI and machine vision to work for and with pathologists, the only company to provide a comprehensive suite of solutions for cancer biopsies relating to gastrointestinal, breast and prostate analysis.


Other news

Upcoming Events


Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2019

Recent advances in cancer diagnostics

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.